Etodolac
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a692015 |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 100% |
| Metabolism | liver |
| Elimination half-life | 7.3 ± 4.0 hours |
| Excretion | renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.157.848 |
| Chemical and physical data | |
| Formula | C17H21NO3 |
| Molar mass | 287.359 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 145 to 148 °C (293 to 298 °F) |
| Solubility in water | 3.92e-02 mg/mL [ALOGPS] mg/mL (20 °C) |
| |
| |
| (verify) | |
Etodolac is a nonsteroidal anti-inflammatory drug (NSAID).
It was patented in 1971 and approved for medical use in 1985. It was approved in the U.S. in 1991.
In 2023, it was the 296th most commonly prescribed medication in the United States, with more than 400,000 prescriptions.